243 related articles for article (PubMed ID: 21902586)
1. Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors.
Espirito-Santo M; Santos-Costa Q; Calado M; Dorr P; Azevedo-Pereira JM
AIDS Res Hum Retroviruses; 2012 May; 28(5):478-85. PubMed ID: 21902586
[TBL] [Abstract][Full Text] [Related]
2. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
[TBL] [Abstract][Full Text] [Related]
3. Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.
Jiang X; Feyertag F; Meehan CJ; McCormack GP; Travers SA; Craig C; Westby M; Lewis M; Robertson DL
J Virol; 2015 Nov; 89(22):11457-72. PubMed ID: 26339063
[TBL] [Abstract][Full Text] [Related]
4. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.
Murga JD; Franti M; Pevear DC; Maddon PJ; Olson WC
Antimicrob Agents Chemother; 2006 Oct; 50(10):3289-96. PubMed ID: 17005807
[TBL] [Abstract][Full Text] [Related]
5. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
[TBL] [Abstract][Full Text] [Related]
6. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex.
Tan Q; Zhu Y; Li J; Chen Z; Han GW; Kufareva I; Li T; Ma L; Fenalti G; Li J; Zhang W; Xie X; Yang H; Jiang H; Cherezov V; Liu H; Stevens RC; Zhao Q; Wu B
Science; 2013 Sep; 341(6152):1387-90. PubMed ID: 24030490
[TBL] [Abstract][Full Text] [Related]
7. [Viral entry as therapeutic target. Current situation of entry inhibitors].
Arenzana-Seisdedos F
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
[TBL] [Abstract][Full Text] [Related]
8. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
Westby M; Lewis M; Whitcomb J; Youle M; Pozniak AL; James IT; Jenkins TM; Perros M; van der Ryst E
J Virol; 2006 May; 80(10):4909-20. PubMed ID: 16641282
[TBL] [Abstract][Full Text] [Related]
9. In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.
Visseaux B; Charpentier C; Hurtado-Nedelec M; Storto A; Antoine R; Peytavin G; Damond F; Matheron S; Brun-Vézinet F; Descamps D;
Antimicrob Agents Chemother; 2012 Jan; 56(1):137-9. PubMed ID: 22064539
[TBL] [Abstract][Full Text] [Related]
10. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
Li Z; Zhou N; Sun Y; Ray N; Lataillade M; Hanna GJ; Krystal M
Antimicrob Agents Chemother; 2013 Sep; 57(9):4172-80. PubMed ID: 23774428
[TBL] [Abstract][Full Text] [Related]
11. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
Panos G; Watson DC
Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
[TBL] [Abstract][Full Text] [Related]
12. Baseline susceptibility of primary HIV-2 to entry inhibitors.
Borrego P; Calado R; Marcelino JM; Bártolo I; Rocha C; Cavaco-Silva P; Doroana M; Antunes F; Maltez F; Caixas U; Barroso H; Taveira N
Antivir Ther; 2012; 17(3):565-70. PubMed ID: 22293827
[TBL] [Abstract][Full Text] [Related]
13. HIV-2 susceptibility to entry inhibitors.
Borrego P; Taveira N
AIDS Rev; 2013; 15(1):49-61. PubMed ID: 23449229
[TBL] [Abstract][Full Text] [Related]
14. Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.
Kramer VG; Schader SM; Oliveira M; Colby-Germinario SP; Donahue DA; Singhroy DN; Tressler R; Sloan RD; Wainberg MA
Antimicrob Agents Chemother; 2012 Aug; 56(8):4154-60. PubMed ID: 22615275
[TBL] [Abstract][Full Text] [Related]
15. Unique Phenotypic Characteristics of Recently Transmitted HIV-1 Subtype C Envelope Glycoprotein gp120: Use of CXCR6 Coreceptor by Transmitted Founder Viruses.
Ashokkumar M; Aralaguppe SG; Tripathy SP; Hanna LE; Neogi U
J Virol; 2018 May; 92(9):. PubMed ID: 29491151
[TBL] [Abstract][Full Text] [Related]
16. An expanded model of HIV cell entry phenotype based on multi-parameter single-cell data.
Bozek K; Eckhardt M; Sierra S; Anders M; Kaiser R; Kräusslich HG; Müller B; Lengauer T
Retrovirology; 2012 Jul; 9():60. PubMed ID: 22830600
[TBL] [Abstract][Full Text] [Related]
17. Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.
Nedellec R; Coetzer M; Lederman MM; Offord RE; Hartley O; Mosier DE
PLoS One; 2011; 6(7):e22020. PubMed ID: 21760945
[TBL] [Abstract][Full Text] [Related]
18. Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications.
Xu GG; Guo J; Wu Y
Curr Top Med Chem; 2014; 14(13):1504-14. PubMed ID: 25159165
[TBL] [Abstract][Full Text] [Related]
19. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
[TBL] [Abstract][Full Text] [Related]
20. C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors.
Hu Q; Huang X; Shattock RJ
J Gen Virol; 2010 Dec; 91(Pt 12):2965-73. PubMed ID: 20810746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
